IMMUNSUPPRESSIVE FORMULIERUNGEN

European patent · EP2661261 · In force

Register entry

Publication number
EP2661261
Application number
EP12700262
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 5, 2012
Published
Nov 13, 2013
Granted
Jul 31, 2019
Protection ends at the latest
Jan 4, 2032
Next annual fee due
Jan 31, 2027
IPC classes
A61K 9/20 (2006.01)
A61K 31/397 (2006.01)
Priority
EP 11150431 07.01.2011
PCT application
PCT/EP2012/050151 05.01.2012
PCT publication
WO2012/093161 12.07.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  5. Jul 31, 2019

    Granted

    Published in Swissreg on 31.07.2019

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

BOUILLOT, Philippe

CH-4002 Basel

REYNAUD, Emeric

CH-4002 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.